Ironwood Pharmaceuticals | IRWD - Cash And Equivalent


Ironwood Pharmaceuticals reported $220.47M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amarin USD 131.06M 3.6M Mar/2026
Ardelyx USD 31.21M 36.79M Mar/2026
Astellas Pharma JPY 188.37B 8.51B Mar/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
Charles River Laboratories USD 191.83M 21.94M Mar/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Moderna USD 1.91B 687M Mar/2026
Myriad Genetics USD 124.4M 25.2M Mar/2026
Pacira USD 144.31M 14.24M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Takeda JPY 654.94B 26.55B Dec/2025
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025